Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds

 
• By Brenda Sandburg
Justice in front of Law
Appeals court revives antitrust claims against Sanofi for improper patent listing in FDA's Orange Book

More from Legal & IP

More from Pink Sheet